Form 4: Elanco CFO Acquires Deferred Stock Units

Elanco Animal Health Inc.'s EVP and CFO, Robert M. VanHimbergen, acquired 8.216 deferred stock units under a pre-arranged plan.

Summary

• Robert M. VanHimbergen, Executive Vice President and Chief Financial Officer of Elanco Animal Health Inc., acquired 8.216 Deferred Stock Units (DSUs).
• The transaction occurred on March 20, 2026, and was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged, non-discretionary acquisition.
• Each DSU represents the right to receive one share of Company common stock or its cash equivalent.
• The DSUs were valued at $23.98 per unit.
• Following this acquisition, Mr. VanHimbergen beneficially owns a total of 48.7929 DSUs.
• These DSUs are scheduled to settle in cash or shares of Company common stock following termination of employment or during a specified future year, in accordance with the Executive Deferral and Stock Match Plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, indicating continued executive alignment with shareholder interests through long-term equity compensation, though it is a routine disclosure.

Positives

• The acquisition of deferred stock units by a key executive like the CFO aligns management's long-term interests with those of shareholders.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-planned and non-discretionary acquisition, which can be viewed favorably as it removes concerns about opportunistic timing.

Future Outlook

The deferred stock units are scheduled to settle in cash or shares of common stock following termination of employment or during a specified future year, aligning executive compensation with long-term company performance and retention goals.

Industry Context

StockSavvy.ai notes that insider acquisitions of deferred stock units, especially by C-suite executives like the CFO, are common mechanisms for executive compensation. These plans often aim to align management's long-term interests with shareholder value creation, a standard practice across the animal health and broader pharmaceutical industries.

Comparison to Industry Standards

• StockSavvy.ai observes that the use of deferred stock units as part of executive compensation is a widely adopted practice among publicly traded companies, including peers in the animal health sector such as Zoetis Inc. (ZTS) and IDEXX Laboratories, Inc. (IDXX).
• The structure, which ties executive wealth to future stock performance and often includes vesting periods or settlement upon employment termination, is consistent with global benchmarks for incentivizing long-term leadership and retention.

Stakeholder Impact

• Shareholders: The executive's increased equity stake aligns their interests with long-term shareholder value creation.
• Employees: Reflects standard executive compensation practices within the company, potentially influencing morale and retention strategies.

Next Steps

• The deferred stock units will settle in cash or shares of Company common stock following termination of employment or during a specified future year, in accordance with the Executive Deferral and Stock Match Plan.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the acquisition of deferred stock units under a pre-arranged plan. While it indicates executive alignment, it does not present new information that would fundamentally alter the investment thesis for Elanco Animal Health Inc. Therefore, a 'hold' recommendation is appropriate as it provides no strong catalyst for a 'buy' or 'sell' decision.

Keywords

Elanco Animal Health, ELAN, Form 4, Insider Transaction, Deferred Stock Units, Executive Compensation, Robert M. VanHimbergen, CFO, Stock Acquisition, Rule 10b5-1